Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(7 sites)
United States
Mayo Clinic, Rochester, Minnesota Nucleus Network, Saint Paul, Minnesota France
Hospices Civils de Lyon- Hôpital Femmes Mères Enfants, Lyon Germany
Kindernierenzentrum Bonn, Bonn United Kingdom
Queen Elizabeth Hospital Birmingham, Birmingham Royal Free Hospital, London